February 01, 2015 3:24 AM ET

Pharmaceuticals

Company Overview of CoLucid Pharmaceuticals, Inc.

Company Overview

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of central nervous system disorders. Its pipeline includes Lasmiditan, a neurally acting anti-migraine agent that is designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies; COL-204 for wake promotion; and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is based in Durham, North Carolina.

2530 Meridian Parkway

Suite 300

Durham, NC 27713

United States

Founded in 2005

Phone:

919-806-4304

Fax:

919-806-4301

Key Executives for CoLucid Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 48
Chief Financial Officer
Legal Counsel and Director
Vice President of Business Development
Vice President of Research & Development
Compensation as of Fiscal Year 2014.

CoLucid Pharmaceuticals, Inc. Key Developments

CoLucid Pharmaceuticals, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:30 AM

CoLucid Pharmaceuticals, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:30 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan

CoLucid Pharmaceuticals, Inc. has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study. The objective of this trial is to evaluate the safety and efficacy of two doses of Lasmiditan in comparison to placebo for the treatment of acute migraine. Patients with risk factors for cardiovascular disease will be included in the study. The SPA agreement includes two novel endpoints for the approval of acute migraine therapies—a primary endpoint of the proportion of patients who are free of headache pain at 2 hours and a key secondary endpoint of the proportion of patients who no longer suffer from their most bothersome associated symptom of migraine (nausea, photophobia, phonophobia) at 2 hours.

CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan

CoLucid Pharmaceuticals, Inc. and ILDong Pharmaceutical Co. Ltd. have entered into a distribution and supply agreement for Lasmiditan in South Korea and Southeast Asia. Under the terms of the agreement, CoLucid will receive upfront and milestone payments in addition to consideration for product supply in exchange for exclusive rights to ILDONG for development and commercialization of Lasmiditan in the territory. ILDONG will be responsible for the costs and activities related to development and regulatory approvals in the territory and will also participate in key registration trials as part of the global development plan.

Similar Private Companies By Industry

Company Name Region
BMP Sunstone Corporation United States
Aurobindo Pharma USA Inc. United States
Zydus Pharmaceuticals (USA) Inc. United States
Sentinella Pharmaceuticals, Inc. United States
Wyeth Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 12, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CoLucid Pharmaceuticals, Inc., please visit www.colucid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.